Tumour growth inhibition (TGI) modelling can be used to capture and predict the effect of anti-cancer agents. These models can be used to predict the effect in both preclinical and human tumours and can be calibrated with monotherapy and combination data.
Physiomics has significant expertise in developing TGI models addressing a huge variety of established and novel targets as well as multiple treatment modalities from radiation and chemotherapy through targeted and immunotherapies.